Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Almost has to be worth a buck or two... wouldn't you think?
wow that's exciting! $QSAM #FDA
Check this out!!!
BIG NEWS!! QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma
08/18/2021
Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has approved QSAM’s application for Orphan Drug Designation of CycloSam® in the treatment of patients diagnosed with osteosarcoma.
Osteosarcoma is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy. Out of five patients who develop or present with metastatic osteosarcoma bone cancer, only one will survive. There have been few advancements over the last 40 years for this deadly disease, and accordingly, there is a large unmet market need for a better treatment that is more efficacious against pediatric osteosarcoma and better tolerated by patients.
“Receipt of Orphan Drug Designation is an important accomplishment for our bone cancer program and for our company. This designation further validates our data-driven approach in oncology drug development and sets the stage for additional aggressive efforts we are undertaking in pediatric and adult cancer therapies,” stated the Company’s CEO, Douglas R. Baum. “Orphan Drug Designation is designed to provide a number of benefits, most notably, seven years of market exclusivity, which complements our growing portfolio of issued patents that we expect will provide us enhanced commercial and market protections.”
Baum continued: “This orphan designation is one of several milestones we have achieved since we started last year working to bring CycloSam through the clinical trial process and ultimately, with FDA approval, to market. We are excited to advance this groundbreaking research to help patients suffering from this devastating disease where the benefits of current treatment options are very limited.”
CycloSam is believed to be a significantly improved formulation of a previously FDA approved radiopharmaceutical. This novel drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Receives-Orphan-Drug-Designation-from-FDA-for-CycloSam-in-the-Treatment-of-Osteosarcoma?id=317010
Psst. Did you see today’s news?
Another building block. Everything that QSAM has done and released has been in the direction of building the company’s future.
I think it could be an incredible ride!
NEWS QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Receives-Patents-in-Japan-and-Canada-Strengthens-Licensed-IP-Portfolio-in-Key-Markets?id=315852
Press Release | 08/11/2021
Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the countries of Japan and Canada have granted patents covering “high purity therapeutic bone agents” in connection with the Company’s CycloSam technology. The United States Patent & Trademark Office (USPTO) issued a patent on this innovation last year.
The patents in Japan and Canada cover technology licensed exclusively on a worldwide basis by QSAM from IGL Pharma, Inc. that protects the use of “low specific activity” Samarium-153. This critical component in CycloSam significantly lowers the amount of long-lived impurities, namely Europium, which may allow for multiple dosing regimens in different types of cancer treatment. The “low specific activity” attribute also allows for the radioisotope to be harvested from the nuclear reactor on a daily basis, instead of weekly, which may permit increased production and facilitate a more efficient and timely supply chain to patients if ultimately approved for commercial use by the FDA.
“We are pleased that the patent offices of Japan and Canada have recognized the novelty of our scientific discoveries and innovations on this key element to CycloSam. This expands our IP estate, consisting of 15 patents among 3 distinct patent families, and broadens our potential commercial market for what we believe can be an important therapy for both primary and secondary forms of bone cancer,” stated Douglas R. Baum, CEO of the Company.
About QSAM Biosciences:
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. QSAM is led by an experienced executive team and Board of Directors with dozens of FDA approvals and multiple successful biotech exits.
CycloSam® has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial successfully performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat primary and secondary bone cancers. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation, and in procedures to reduce external beam radiation. This multi-patented drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models and veterinary treatment of cancer in dogs. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam®.
The Dr.s on board have gone through FDA approval numerous times, not their first rodeo. This is a different company than it was with pooh power...
congrats Nice move I also bought heavy after reverse but not as smart as you as I did not sell them and bought all the way down and it looks like I picked up a lot of the loose paper. Locked and loaded for a positive news release. If they do not get the IND which they should I am screwed. Risk / reward extremely high IMHO!
Yeah I think the time for building a position at the bid has passed. We’ll see.
Agreed. Before and After the reverse I had been accumulating. At one point I owned 10% of the public float. With the restructuring a lot of debt was converted into shares and some added to the float.
I sold most of my position as it traded up afterwards. In the last month I’ve built up a modest position.
This wound so tight I can feel it squeeze like a python!
Randy we seem to find a few gems that are undiscovered by ihub. This is not a popular stock yet but I think once IND is approved it will be discovered by the masses. Nice to see you here a while ago!
I agree paper drying up or gone! Good news and this is a rocket. Shares have been accumulated over the last few months from loose paper now is the time for good news.
I think you’re right. QSAM is found a lot right. I don’t have any way to know how much paper remains, but it certainly seems to be tailing off.
Looks as if the paper has been eaten up and ready for a run if they get good news from the FDA
When you realize this is a tradable company for no other reason than leverage to raise capital and there is no concern over increasing share holder value at all... it makes seeing the current share price sting less.
5 months ago.... $0.85...
Yesterday.... QSAM BioSciences Inc (QSAM) 0.2776
meanwhile every other stock I'm holding has grown 15% in the same time period.. well except CYPW which was finally delisted... and if you know the connection to QSAM you understand why.
What happened to all the pumpers?
-Chuck
Someone wake this stock up Rip Van Sleeper!
I was bid shopping to clean up the toxic paper. Paper should be gone, now we should start the rise in stock price and progress toward phase one trial! I was able to amass a large position so I will be a hero or a zero time will tell....
This aged well... stock price was $0.85 when this originally posted.
Today: QSAM BioSciences Inc (QSAM) 0.3712
-Chuck
in addition to a Payroll Protection Program loan received in 2020 which we expect to be forgiven in future periods.
The dramatic change in our cash and equity position resulted from the conversion to common stock of all Bridge Notes, which were previously in default, and additional common stock conversions of debentures and payables
Our operating expenses of $3.3 million increased significantly, all but $288,000 of these operating expenses were comprised of non-cash charges primarily from stock-based compensation, mostly in the form of restricted, vesting and forfeitable Series E-1 Preferred Stock to the officers, directors and key employees, and short-term common stock warrants issued to a service provider. We expect the accrual of preferred stock-based compensation expenses to be similar in the second quarter, with these expenses tapering off in the second half of 2021.
Our current overhead run-rate is low with all executives of the Company choosing to receive only a portion of their salaries during our initial development stage.
QSAM Biosciences Issues Letter from CEO on Successful First Quarter 2021
https://finance.yahoo.com/news/qsam-biosciences-issues-letter-ceo-130000884.html
Austin, TX, May 25, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:
Dear Shareholders:
QSAM Biosciences had a transformative first quarter of 2021. We want to take this opportunity to summarize the progress we’ve made since the end of 2020, much of which can be found on our Form 10-Q filed with the SEC on May 20, 2021, as well as the latest on the development of our core radiopharmaceutical technology, CycloSam®.
Key Take-Aways from our March 31, 2021 Financial Statements and 10-Q
On May 20, we filed our Form 10-Q for the first quarter of 2021. The financial statements presented in that filing show a significantly improved balance sheet from December 31, 2020, and in fact, present the strongest position the Company has been in since inception. Most notably, we reported at the end of March:
$1.94 million in available cash, up from $8,300 at the end of 2020;
$389,000 of total current liabilities, down from $4.19 million at the end of 2020; and
$821,000 of Shareholder Equity, up from a Shareholder Deficit of $5.1 million at the end of 2020.
The dramatic change in our cash and equity position resulted from the completion of our $2.5 million Series B Preferred Stock offering in January 2021, as well as the conversion to common stock of all Bridge Notes, which were previously in default, and additional common stock conversions of debentures and payables in the quarter. As of March 31, 2021, we only had $35,000 of debentures outstanding in addition to a Payroll Protection Program loan received in 2020 which we expect to be forgiven in future periods.
On our Statement of Operations, we showed no revenue for the quarter, which is to be expected for a company advancing the development of a drug technology. Our operating expenses of $3.3 million increased significantly in the first quarter of 2021 over 2020; however, all but $288,000 of these operating expenses were comprised of non-cash charges primarily from stock-based compensation, mostly in the form of restricted, vesting and forfeitable Series E-1 Preferred Stock to the officers, directors and key employees, and short-term common stock warrants issued to a service provider. We expect the accrual of preferred stock-based compensation expenses to be similar in the second quarter, with these expenses tapering off in the second half of 2021.
Our total losses of $4.4 million in the first quarter of 2021 also included approximately $1.2 million in non-cash charges from the conversion of almost all remaining debt to equity in the period (as discussed above), offset by a $100,000 gain from the sale of our remaining equity interests in our legacy business.
Our current overhead run-rate is low with all executives of the Company choosing to receive only a portion of their salaries during our initial development stage. At the current rate, we would expect cash on hand to last into early 2022. However, we believe operations are about to accelerate for QSAM as we enter clinical trials for our lead drug candidate CycloSam, and as such, expenses will increase as we start to dose patients afflicted with metastatic bone cancer and primary bone cancer, which is the focus of our upcoming Phase 1 study.
Updates on Operations and Clinical Development
From an operational perspective, we have already achieved several important milestones projected last month, namely:
In late April we filed our IND with the FDA, the clearance of which will allow us to start dosing patients in our Phase 1 trials for CycloSam. This is a dose escalating open study, so we would expect to start seeing actual efficacy results that may be reportable in early 2022.
We executed an agreement with an experienced Contract Research Organization (CRO) to provide full clinical trial management, monitoring, data management, statistical analysis and medical writing services in association with conducting our upcoming Phase I clinical trial. Work commenced under this agreement in the first quarter of 2021.
We added to our team Richard K. Burt, M.D, as a member of the Company’s Scientific Advisory Board. Dr. Burt is a world-renowned pioneer in stem cell transplants, which is an area our bone cancer therapy technology touches in many different aspects, and his experience should help advance our clinical trials and possibility open new potential indications for our drug candidate.
With respect to the start of our clinical trials, last week QSAM engaged with the FDA regarding our IND filing for CycloSam. The call was very cooperative in tone and content, and the QSAM team was able to convey a better understanding of the clinical direction and the potential utility of CycloSam. The FDA will be requesting additional information and clarification over the near term and we will work promptly to resolve all FDA clinical hold questions and comments before proceeding with our Phase I study.
Important Milestones for the Coming Year.
In the near term we are working to achieve the following additional milestones:
Clearance of our IND with the FDA to start clinical trials with CycloSam;
Dosing of the first patient in the Phase 1 trials with CycloSam;
Announcement of initial Phase 1 results of CycloSam (possibly in 2022);
Expansion of our intellectual property portfolio with newly issued patents; and
Possible acquisition of a second radiopharmaceutical asset to expand our product pipeline.
Should we be able to achieve these milestones and other regulatory qualifications can be met, it is our intention to seek a NASDAQ up-listing on our common shares in 2022.
This is truly an exciting time for QSAM and its shareholders, as we believe the Company is now positioned for meaningful value appreciation over the following months and year.
Sincerely,
Douglas R. Baum
Chief Executive Officer
Agreed... Tell progress being made on a drug with real potential.
I think there are a lot of the shares entering the market. Debt conversion and IR most likely.
The high dosage medicine VERSES the side effect are off the charts. Just read PR's I even noticed this huge anomaly.
No doubt they could benefit kids and anyone else who has bone cancer. CycloSam is being developed by the same two people who developed Quadramet. However, my understanding from the company investor deck is that it is 40x less harmful or toxic to the body as Quadramet is. So that should be well received by the FDA. Glad you reached out to David. He seems like a good IR guy to have in our corner.
I took your advice and reached out to him. He said QSAM filed the IND a week before the PR came out, so they could be in Phase 1 next week. He also said "Cyclosam is the same drug as Lantheus' (NASDAQ: LNTH) FDA approved drug, Quadramet. QSAM filed its IND on Cyclosam for the treatment of bone cancer. Lantheus has FDA approval for the drug as a pain treatment for cancer patients." The two guys who's pictures are at the bottom of the management profile are the inventors. It sounds like QSAM and CycloSam could benefit kids with bone cancer.
It looks like there are one or two small time sellers. I've been able to buy some stock on the bid.
Thanks for the input. Good to hear. Is your daughter familiar with various cancer treatments? What blew her away by the med?
I looked at the product and the people and saw bingo in the future.
tired of waiting I slapped the ask. Loaded the boat. My daughter is a nurse and she was blown away by the product.
If you have any questions, recommend reaching out to him directly. He is very responsive. I was the first investor to have reached out to him.
Thanks.
I own quite a few shares.
This outfit sounds super legit.
http://www.atlcp.com/about/default.html
as does David Kugelman.
Had some back and forth email communication with the President and CEO of the firm now leading Investor Relations for QSAM, the man whose name now appears on the Press Releases. Was very impressed with the timing of his response and the in depth answers to my questions. In short the thing he said that struck me the most was that given his extensive experience in IR and financial banking (which is vast) he has to really believe in a company before they get involved. Never been more confident in my investment.
I put up a fat bid for anyone to get out now go hit it!
Whoa! QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA
I wasn't expecting this? QSAM is for real. From the FDA's web site "Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk."
https://finance.yahoo.com/news/qsam-biosciences-announces-submission-ind-130000188.html
I'm very optimistic near-term. Even more optimistic longer term.
Time to load up here at $0.40.
Dr. Burt, a world renowned stem cell and award winning doctor, is a great add to their Advisory Board. To give you an idea of the caliber of doctor he is, here is a link showcasing Dr. Burt on CBS This morning
$QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
https://finance.yahoo.com/news/qsam-biosciences-appoints-richard-k-130000854.html
Austin, TX, April 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today that it has appointed Richard K. Burt, M.D., to its Scientific Board of Advisors.
“Stem cell procedures, in which Dr. Burt is a world-renowned expert, are a core safety measure to some of the high dose indications we envision for our lead radiopharmaceutical candidate, CycloSam®, due to the way radiation therapy is delivered to the bone. We also see bone marrow ablation prior to a stem cell transplant, similar to the procedure we performed on a patient last year, and potential future uses to treat sickle cell disease, as key indications for our technology,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “We believe Dr. Burt will bring invaluable clinical guidance to the development of CycloSam, and we are enthusiastic about the contributions he will make to our long-term success.”
Over the last 35 years, Dr. Burt pioneered the use of hematopoietic stem cells to treat autoimmune diseases and he was among the first doctors in the United States and the World to perform autologous hematopoietic stem cell transplants for numerous immune–mediated diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Crohn’s disease, type 1 diabetes, and other serious conditions. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10 million multi-center contract to develop stem cell clinical trials for autoimmune diseases.
In 2006, Dr. Burt was recognized by Scientific American along with Al Gore and Steve Jobs as one of the top 50 people in the world for improving humanity due to his pioneering stem cell work. In 2011, Science Illustrated recognized Dr. Burt’s stem cell work as one of the top 10 advances of the decade.
About QSAM Biosciences:
QSAM Biosciences, Inc. holds the worldwide license for CycloSam® (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc and subsequently exclusively licensed to QSAM Biosciences, Inc.
CycloSam® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA-approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.
CycloSam® is cleared by the FDA under an investigator initiated IND to commence human dosing in patients with osteosarcoma and bone metastasis. CycloSam® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.
Legal Notice Regarding Forward-Looking Statements: This news release contains "Forward-looking Statements". These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Contact
David L. Kugelman
Atlanta Capital Partners LLC
T: (404) 856-9157
Thanks Solong!! I missed this newfound released.
It's pretty clear management has pretty big plans for the future. Or seems to me they've put together a pretty decent team to make it happen.
$QSAM - letter out from the CEO
https://www.globenewswire.com/news-release/2021/04/19/2212454/0/en/QSAM-Biosciences-Issues-Letter-from-CEO-on-Successful-Achievements-and-Future-Milestones-for-Company.html
Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:
Dear Shareholders:
We are pleased to report that 2020 was pivotal year for QSAM Biosciences as we established the foundation for significant advancements in 2021, several of which have already been achieved. We want to take this opportunity to summarize some of the more material items that we believe will help build value for our shareholders in the years ahead, and which are also detailed in our Form 10-K filed with the SEC on April 15, 2021.
During 2020 and the first quarter of 2021 we accomplished the following:
Secured promising drug technology to treat bone cancer: In April 2020, we licensed on a worldwide, exclusive basis a novel and patented radiopharmaceutical called CycloSam®, meant to target cancers that develop in or metastasize to the bone. CycloSam is a significantly improved version of another FDA approved and commercialized radiopharmaceutical developed by the same inventors, but with the possibility of broader commercial indications. Preliminary results of early studies support a potentially favorable safety and efficacy profile of CycloSam. As a result of this, as well as a number of animal studies and one human trial conducted this past summer, and the streamlined manufacturing process that is already in place, we are optimistic about the chances of advancing CycloSam through the FDA process over the coming years.
Established a team of seasoned biotech experts: In November we appointed as our new Executive Chairman, C. Richard Piazza, who has more than 45 years of healthcare experience in both medical devices and pharmaceutical/biotech development and has led several technology companies to market success including numerous FDA approvals in both sectors. The company also appointed me, Douglas Baum, as our new CEO. I personally bring over 28 years of experience in the bioscience and biotech industries, overseeing 15 product approvals through the FDA. In February 2021, we appointed a new independent director, Dr. Charles J. Link Jr., who brings decades of biotech and drug development experience to QSAM, including serving as CEO, CSO, Chairman, and founder of NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates.
Completed $2.5 million in new equity funding: In November we commenced our Series B preferred stock offering, and by January 2021 had closed on $2.5 million in funding (inclusive of $156,000 in debt conversion) to support our clinical trials and operations through 2021. In connection with this offering, we also issued short-term warrants that, if exercised, could provide another $2 million in funding around the end of the second quarter of 2021.
Significantly reduced our debt and divested our legacy business: In November we signed a separation agreement which transferred to a related party called Earth Property Holdings (EPH) our soil business and assets in return for the extinguishment of almost $1 million in debt and the conversion into common stock of a $117,000 note. By the end of 2020, we had converted approximately an additional $3.3 million of promissory notes, accrued compensation and other liabilities into common stock; and by March 31, 2021, we had eliminated the remaining amount of approximately $1.5 million in debt, leaving just $35,000 in convertible debentures currently on our books. In connection with the equity raise completed in January, our balance sheet as of the present date has never been stronger.
Building upon this solid foundation, through 2021 we expect to demonstrate advancements from the achievement of several important milestones, including:
Filing and ultimate clearance of our IND with the FDA to start clinical trials with CycloSam;
Dosing of the first patient in the Phase 1 trials with CycloSam;
Announcement of initial Phase 1 results of CycloSam (possibly in 2022);
Expansion of our intellectual property portfolio with newly issued patents;
Possible acquisition of a second radiopharmaceutical asset to expand our product pipeline; and
Adding additional biotech expertise to our team.
Sounds like a winning strategy. I've done the same.
So don't buy the stock? If you really think it's garbage, short it. I like the way the company management looks. I've also taken my original investment off of the table and I'm going to let the rest ride.
For those who want to ignore the man behind the curtain, the proof is in the filings...
Filing late is a SOP of Nelson.. expect there to be some type of news that will increase the share price in the short term.. then when the fillings occur there will be a drop....
Date: March 31, 2021 By: /s/ Christopher Nelson
Name: Christopher Nelson
Title: General Nelson
Thanks. It's seems he's finally putting his credentials to work.
I'm not absolutely sure, but I think there's some money to be have here.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
931
|
Created
|
01/15/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |